Clinical Trial Update: Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Campath-1H (alemtuzumab) for preventing kidney transplant rejection has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Transplant Rejection

Drugs mentioned

• Campath-1H (alemtuzumab)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Graft Rejection, Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2010-10-05